Sorrento Therapeutics, Inc. (SRNE)
Sorrento Therapeutics, Inc. is a biopharmaceutical company, active in both clinical development and commercial operations, dedicated to creating treatments for a range of serious conditions including cancer, autoimmune disorders, inflammatory diseases, viral infections, and neurodegenerative ailments. The company's operations are divided into two distinct segments: Sorrento Therapeutics and Scilex. A core focus lies in cancer therapeutics, where Sorrento harnesses its proprietary G-MAB antibody library. This is complemented by advanced, targeted delivery systems such as chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, antibody-drug conjugates, and innovative bispecific antibody approaches. Additionally, their Sofusa drug delivery technology offers a unique method for introducing biologics directly into the lymphatic system. Sorrento's clinical pipeline features several promising candidates. These include an anti-CD38 CAR-T therapy currently being developed for multiple myeloma, amyloidosis, and graft-versus-host disease. They are also advancing resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin, for managing late-stage cancer pain and osteoarthritis knee pain. Furthermore, ZTlido, a lidocaine delivery system, addresses postherpetic neuralgia. Other significant developments comprise SEMDEXA, an injectable viscous gel in Phase III trials for sciatica, a specific form of low back pain; SP-103, an investigational non-aqueous lidocaine topical system targeting chronic low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for fibromyalgia treatment. The company actively engages in strategic collaborations, including partnerships with SmartPharm Therapeutics Inc. to develop a gene-encoded antibody vaccine against COVID-19, and with Celularity, Inc. for a Phase I/II clinical study involving up to 94 COVID-19 patients. Sorrento also works with the Mount Sinai Health System on COVI-SHIELD, an antibody therapy designed to combat SARS-CoV-2 infection, and with the Mayo Clinic on a Phase Ib pilot study utilizing the Sofusa lymphatic drug delivery technology for Ipilimumab in melanoma patients. Established in 2006, Sorrento Therapeutics, Inc. is headquartered in San Diego, California.
Sector: Biotechnology
Industry: Biotechnology
Sorrento Therapeutics, Inc.
OTC:SRNEHealthcare · Biotechnology
$0.0003
CLOSED · Nov 6Prev close$0.0003Close$0.0003
Mkt Cap$165K
Float539.11M
O/S551.28M
VOL51K sh
$ Vol$15
RVOL0.67×
Inst Own-
SI0.7%
Dilution
Financials Summary
Revenue$62.84M
Net Income-$572.84M
Total Assets$472.84M
Free Cash Flow-$307.51M
Debt & Equity
Debt 116%
Total Debt$134.5M
Total Equity-$18.61M
Shares Outstanding
Short Interest
Split History1 split · 1 reverse
- 1:25Reverse splitAug 1, 201325 shares → 1
Balance Sheet Details
Assets$472.84M
Liabilities$494.51M
Accounts Receivable$24.47M
Accounts Payable$47.52M
Inventory$9.98M
PP&E (Net)$138.44M
Goodwill$80.27M
Intangible Assets$136.9M
Income Statement
| Period | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 | 2005-12-31 | 2004-12-31 | 2003-12-31 |
| Revenue | $62.84M | $52.9M | $39.99M | $31.43M | $21.19M | $151.86M | $8.15M | $4.59M | $3.83M | $460K | $584K | $529K | $683K | $5K | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | 18.8% | 32.3% | 27.2% | 48.3% | -86.0% | 1762.8% | 77.6% | 20.0% | 731.3% | -21.2% | 10.3% | -22.5% | 12509.8% | - | - | - | - | - | - | - |
| Cost of Revenue | $33.45M | $13.03M | $9.94M | $12.24M | $10.07M | $11.03M | $3.7M | $1.95M | $2.04M | $4K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Profit | $29.39M | $39.87M | $30.05M | $19.2M | $11.12M | $140.83M | $4.46M | $2.64M | $1.78M | $456K | $584K | $529K | $683K | $5K | $0 | $0 | $0 | $0 | $0 | $0 |
| Gross Margin | 46.8% | 75.4% | 75.1% | 61.1% | 52.5% | 92.7% | 54.7% | 57.5% | 46.6% | 99.0% | 100.0% | 100.0% | 100.0% | 100.0% | - | - | - | - | - | - |
| Research and Development | $221.23M | $206.92M | $111.34M | $106.88M | $76.96M | $55.53M | $42.17M | $31.34M | $23.98M | $9.02M | $3.83M | $2.57M | $1.39M | $410K | $0 | $0 | $0 | $0 | $0 | $0 |
| Selling, General, and Administrative | $182.34M | $196.86M | $116.18M | $103.56M | $63.64M | $32.96M | $22.18M | $20.13M | $9.99M | $6.32M | $1.61M | $1.2M | $1.1M | $544K | $191K | $241K | $439K | $0 | $0 | $0 |
| Other | $130.14M | $4.14M | $4.05M | $3.94M | $0 | $0 | $0 | $1.16M | $2.35M | $804K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | -$308K | -$763 | -$763 |
| Total Operating Expenses | $533.7M | $407.92M | $231.57M | $214.38M | $140.6M | $88.49M | $64.35M | $52.63M | $36.31M | $16.14M | $5.44M | $3.77M | $2.49M | $954K | $191K | $241K | $439K | -$308K | -$763 | -$763 |
| Operating Income (EBIT) | -$504.31M | -$368.05M | -$201.53M | -$195.18M | -$129.48M | $52.34M | -$59.9M | -$74M | -$34.74M | -$21.67M | -$4.85M | -$3.24M | -$1.81M | -$954K | -$191K | -$241K | -$439K | -$308K | -$763 | -$763 |
| Operating Margin | -802.6% | -695.7% | -504.0% | -621.0% | -610.9% | 34.5% | -734.8% | -1612.3% | -908.3% | -4708.9% | -831.2% | -612.7% | -265.5% | -17626.5% | - | - | - | - | - | - |
| Interest Expense | $8.57M | $10.22M | $20.18M | $36.14M | $57.63M | $4.98M | $1.61M | $1.65M | $1.63M | $253K | $7K | $0 | $0 | $12K | $2K | $0 | $0 | $0 | $0 | $763 |
| Interest Income | $0 | $0 | $24K | $1.09M | $921K | $241K | $272K | $24K | $12K | $10K | $7K | $6K | $4K | $12K | $2K | $9 | $0 | $0 | $0 | $0 |
| Other Income (Expense) | -$57.43M | -$94.48M | -$114.9M | -$100.18M | -$63.36M | -$10.02M | -$4.93M | $36.23M | -$1.62M | -$6.23M | $7K | $6K | $4K | $12K | $0 | -$30K | $0 | -$308K | $0 | $0 |
| Income Before Tax (EBT) | -$561.75M | -$462.53M | -$316.42M | -$359.58M | -$213.78M | $15.31M | -$64.83M | -$13.76M | -$36.36M | -$21.91M | -$4.85M | -$3.24M | -$1.81M | -$942K | $0 | -$271K | $0 | -$616K | $0 | $0 |
| Income Tax Expense | -$2.42M | -$33.52M | -$2.01M | -$473K | -$6.27M | -$36.04M | -$896K | $36.31M | -$1.7M | $10K | $15K | $12K | $8K | $0 | -$2K | -$9 | $439K | -$308K | $763 | $763 |
| Net Income | -$572.84M | -$429.01M | -$298.46M | -$359.1M | -$203.54M | $9.06M | -$60.92M | -$45.81M | -$34.66M | -$21.91M | -$4.85M | -$3.24M | -$1.81M | -$942K | -$189K | -$271K | -$439K | -$308K | -$763 | -$763 |
| Net Income Margin | -911.6% | -810.9% | -746.4% | -1142.5% | -960.4% | 6.0% | -747.3% | -998.1% | -906.1% | -4761.8% | -830.0% | -611.6% | -264.9% | -17407.5% | - | - | - | - | - | - |
| Supplementary Data | ||||||||||||||||||||
| EPS | -1.37 | -1.46 | -1.30 | -2.56 | -1.92 | 0.13 | -1.21 | -1.24 | -1.30 | -1.46 | -0.42 | -0.33 | -0.20 | -0.15 | -0.50 | -1.05 | -15.46 | -10.84 | -0.03 | -0.03 |
| Diluted EPS | -1.37 | -1.46 | -1.30 | -2.56 | -1.92 | 0.13 | -1.21 | -1.24 | -1.30 | -1.46 | -0.42 | -0.33 | -0.20 | -0.15 | -0.50 | -1.05 | -15.46 | -10.84 | -0.03 | -0.03 |
| Weighted Average OS | 419.31M | 294.77M | 229.82M | 140.51M | 106.15M | 69.74M | 50.36M | 36.91M | 26.68M | 15.05M | 11.41M | 9.92M | 8.83M | 6.08M | 378,022 | 257,929 | 28,409 | 28,409 | 28,409 | 28,409 |
| EBITDA | -$539.93M | -$439.84M | -$279.42M | -$313.54M | -$147.1M | $27.38M | -$60.34M | -$9.74M | -$31.55M | -$20.37M | -$4.55M | -$3.08M | -$1.78M | -$940K | -$187K | -$241K | -$439K | -$308K | -$763 | -$763 |
| EBITDA Margin | -859.2% | -831.4% | -698.8% | -997.5% | -694.1% | 18.0% | -740.2% | -212.2% | -824.7% | -4426.3% | -779.8% | -581.5% | -261.5% | -17356.6% | - | - | - | - | - | - |
Balance Sheet
| Period | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 | 2005-12-31 | 2004-12-31 | 2003-12-31 |
| Assets | ||||||||||||||||||||
| Current Assets | ||||||||||||||||||||
| Cash and Cash Equivalents | $23.63M | $36.66M | $56.46M | $22.52M | $168.33M | $20.43M | $82.4M | $39.04M | $71.9M | $31.67M | $5.09M | $3.47M | $5.28M | $3.43M | $380K | $22K | $0 | $0 | $0 | $0 |
| Short-Term Investments | $26.34M | $90.22M | $0 | $0 | $297K | $441K | $1.11M | $97.37M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Cash and Short-Term Investments | $49.98M | $126.88M | $56.46M | $22.52M | $168.63M | $20.87M | $83.5M | $136.4M | $71.9M | $31.67M | $5.09M | $3.47M | $5.28M | $3.43M | $380K | $22K | $0 | $0 | $0 | $0 |
| Accounts Receivable | $24.47M | $18.71M | $15.51M | $14.51M | $4.36M | $3.93M | $2.98M | $2.62M | $732K | $394K | $80K | $61K | $246K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | $9.98M | $8.11M | $1.83M | $3.36M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Assets | $3.14M | $7.48M | $3.72M | $15.44M | $6.58M | $4.9M | $0 | $2M | $1.28M | $571K | $81K | $30K | $0 | $28K | $14K | $0 | $0 | $0 | $0 | $0 |
| Total Current Assets | $96.37M | $172.99M | $86.23M | $67.59M | $179.56M | $29.7M | $89.65M | $141.02M | $73.92M | $32.63M | $5.25M | $3.56M | $5.55M | $3.46M | $395K | $22K | $0 | $0 | $0 | $0 |
| Long-Term Assets | ||||||||||||||||||||
| Property, Plant & Equipment Net | $138.44M | $126.5M | $73.91M | $76.27M | $24.38M | $19.34M | $12.71M | $7.25M | $2.28M | $2.44M | $1.48M | $988K | $96K | $73K | $0 | $0 | $0 | $0 | $0 | $0 |
| Goodwill | $80.27M | $79.53M | $43.55M | $38.3M | $38.3M | $38.3M | $41.55M | $20.63M | $24.04M | $24.04M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $136.9M | $259.7M | $73.67M | $63.31M | $66.28M | $71.01M | $64.77M | $3.91M | $30.98M | $33.32M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Investments | $17.18M | $51.27M | $256.4M | $262.24M | $309.99M | $270.01M | $189M | $170.13M | $10M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $78.08M | $62.93M | $60.35M | $50.64M | $48.16M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $3.69M | -$73.25M | -$60.88M | -$10.43M | $5.57M | $3.25M | $3.91M | $590K | $332K | $148K | $49K | $23K | $38K | $23K | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Assets | $376.47M | $521.83M | $449.59M | $490.04M | $495.16M | $450.08M | $311.93M | $202.5M | $67.63M | $59.95M | $1.53M | $1.01M | $134K | $96K | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $472.84M | $694.82M | $535.82M | $557.63M | $674.73M | $479.78M | $401.59M | $343.52M | $141.54M | $92.58M | $6.78M | $4.57M | $5.69M | $3.55M | $395K | $22K | $0 | $0 | $0 | $0 |
| Liabilities | ||||||||||||||||||||
| Current Liabilities | ||||||||||||||||||||
| Accounts Payable | $47.52M | $27.41M | $24.71M | $27.63M | $13.82M | $9.91M | $8.28M | $1.34M | $1.66M | $2.15M | $440K | $225K | $182K | $316K | $117K | $3K | $472K | $33K | $84K | $84K |
| Short-Term Debt | $16.29M | $31.98M | $23.21M | $39.58M | $10.15M | $0 | $209K | $4.83M | $3.32M | $374K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $10K | $10K |
| Current Income Tax Payable | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Unearned Revenue | $652K | $1.11M | $4.49M | $3.64M | $2.7M | $3.86M | $9.67M | $110.9M | $1.1M | $0 | $0 | $0 | $200K | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Current Liabilities | $241.71M | $45.91M | $19.6M | $24.21M | $34.95M | $65.18M | $1.26M | -$86.2M | $3.49M | $2.95M | $145K | $135K | $54K | $37K | -$115K | $0 | $0 | $0 | $247K | $246K |
| Total Current Liabilities | $327.92M | $139.45M | $96.48M | $115.21M | $61.62M | $78.95M | $76.08M | $30.87M | $9.56M | $5.48M | $584K | $359K | $604K | $353K | $2K | $3K | $472K | $33K | $341K | $340K |
| Long-Term Liabilities | ||||||||||||||||||||
| Long-Term Debt | $19.13M | $110.63M | $92.26M | $199.09M | $223.14M | $5.21M | $47.11M | $4.39M | $8.83M | $4.43M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $7.1M | $118.94M | $113.19M | $114.39M | $116.27M | $119.29M | $134.38M | $110.9M | $1.1M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Deferred Tax Liabilities | $591K | $2.43M | $6.92M | $9.04M | $60.05M | $63.7M | $53.24M | $49.34M | $12.55M | $14.25M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $54.56M | $161.81M | $35.95M | $35.04M | $6.14M | $6.01M | $4.28M | $7.07M | $796K | $1.61M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Long-Term Liabilities | $166.59M | $477.24M | $298.61M | $409.67M | $405.6M | $194.21M | $239M | $171.71M | $23.27M | $20.29M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $494.51M | $616.69M | $395.09M | $524.88M | $467.23M | $273.17M | $315.08M | $202.58M | $32.83M | $25.77M | $584K | $359K | $604K | $353K | $2K | $3K | $472K | $33K | $341K | $340K |
| Stockholders' Equity | ||||||||||||||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $52K | $32K | $28K | $18K | $13K | $9K | $6K | $4K | $4K | $2K | $30K | $26K | $25K | $23K | $1K | $8K | $14K | $14K | $14K | $14K |
| Retained Earnings | -$1.96B | -$1.39B | -$958.28M | -$659.82M | -$367.75M | -$165.12M | -$174.25M | -$113.33M | -$67.52M | -$32.86M | -$10.95M | -$6.1M | -$2.87M | -$1.06M | -$1.66M | -$1.47M | -$1.2M | -$764K | -$1.07M | -$1.07M |
| Comprehensive Income & Other | $1.5M | $1.03M | $520K | -$270K | $15K | $242K | -$118K | $73.58M | -$1.69M | -$933K | -$479K | -$185K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Stockholders' Equity | $1.94B | $1.47B | $1.12B | $738.39M | $577.21M | $364.68M | $254.28M | $258.48M | $176.23M | $99.67M | $17.12M | $10.29M | $7.93M | $4.24M | $2.05M | $1.48M | $717K | $717K | $717K | $717K |
| Total Equity | -$18.61M | $78.75M | $165.15M | $78.59M | $209.47M | $199.57M | $80.04M | $145.15M | $108.71M | $66.81M | $6.2M | $4.21M | $5.08M | $3.2M | $392K | $19K | -$472K | -$33K | -$341K | -$340K |
| Minority Interest | -$3.06M | -$619K | -$24.42M | -$45.83M | -$1.97M | $7.04M | $6.46M | -$4.21M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities and Equity | $475.9M | $695.44M | $560.24M | $603.46M | $676.7M | $472.73M | $395.12M | $347.73M | $141.54M | $92.58M | $6.78M | $4.57M | $5.69M | $3.55M | $395K | $22K | $0 | $0 | $0 | $0 |
| Supplementary Data | ||||||||||||||||||||
| Total Debt | $134.5M | $237.58M | $169.39M | $294.1M | $233.29M | $5.21M | $47.32M | $9.23M | $12.15M | $4.8M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $10K | $10K |
| Net Debt | $110.87M | $200.91M | $112.93M | $271.58M | $64.96M | -$15.22M | -$35.08M | -$29.81M | -$59.76M | -$26.86M | -$5.09M | -$3.47M | -$5.28M | -$3.43M | -$380K | -$22K | $0 | $0 | $10K | $10K |
Cash Flow Statement
| Period | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 | FY 2015 | FY 2014 | FY 2013 | FY 2012 | FY 2011 | FY 2010 | FY 2009 | FY 2008 | FY 2007 | FY 2006 | FY 2005 | FY 2004 | FY 2003 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 | 2017-12-31 | 2016-12-31 | 2015-12-31 | 2014-12-31 | 2013-12-31 | 2012-12-31 | 2011-12-31 | 2010-12-31 | 2009-12-31 | 2008-12-31 | 2007-12-31 | 2006-12-31 | 2005-12-31 | 2004-12-31 | 2003-12-31 |
| Operating Activities | ||||||||||||||||||||
| Net Income | -$577.76M | -$429.14M | -$314.41M | -$363.01M | -$203.54M | $9.06M | -$60.92M | -$50.07M | -$34.66M | -$21.91M | -$4.85M | -$3.24M | -$1.81M | -$942K | -$189K | -$271K | -$439K | $308K | -$763 | -$763 |
| Depreciation & Amortization | $13.24M | $12.46M | $11.01M | $10.99M | $9.05M | $7.08M | $2.88M | $2.37M | $3.18M | $1.29M | $293K | $159K | $23K | $3K | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Income Tax | -$1.84M | -$35.93M | -$2.13M | -$373K | -$6.12M | -$35.68M | $982K | $33.34M | -$1.7M | $0 | $0 | $3.24M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Stock-Based Compensation | $74.85M | $90.19M | $31.42M | $12.65M | $0 | $4.95M | $4.74M | $6.97M | $3.94M | $1.79M | $863K | $298K | $251K | $55K | $0 | $0 | $0 | $0 | $0 | $0 |
| Changes in Working Capital: | ||||||||||||||||||||
| Accounts Receivable | -$5.68M | -$2.96M | -$1.05M | -$10.62M | -$1.62M | -$515K | -$472K | -$176K | $0 | $117K | -$19K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Inventory | -$9.51M | $8.62M | $10.2M | $0 | $0 | $0 | $0 | $7.82M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | $9.87M | -$3.88M | -$3.68M | $10.22M | $3.58M | $1.59M | $3.71M | -$2.71M | -$497K | $879K | -$23K | $43K | -$135K | $145K | -$953 | -$469K | $0 | $0 | $0 | $0 |
| Other Working Capital | $74.87M | -$4.57M | -$1.68M | $0 | $4.04M | -$18.68M | $22.3M | $9.88M | $275K | -$557K | -$67K | -$7K | $122K | $5K | -$14K | $0 | $0 | -$298K | $0 | $763 |
| Total Working Capital Change | $69.55M | -$2.79M | $3.8M | $7.25M | $6M | -$17.6M | $25.54M | $14.8M | -$222K | $438K | -$109K | $36K | -$13K | $150K | -$15K | -$469K | $439K | -$298K | $763 | $763 |
| Other Non-Cash Items | $128.09M | $83.39M | $110.77M | $159.5M | $98.99M | -$48.96M | -$36.85M | -$49.48M | $693K | $1.9M | $0 | -$3.24M | $0 | $0 | $0 | $71K | $0 | $0 | $0 | $0 |
| Net Cash from Operating | -$293.86M | -$281.82M | -$159.54M | -$173M | -$111.77M | -$99.18M | -$70.89M | -$42.07M | -$28.76M | -$16.49M | -$3.8M | -$2.74M | -$1.55M | -$735K | -$204K | -$668K | $0 | $10K | $0 | $0 |
| Investing Activities | ||||||||||||||||||||
| Capital Expenditures | -$13.66M | -$8.87M | -$37.58M | -$11.44M | -$21.2M | -$10.97M | -$6.86M | -$3.71M | -$591K | -$931K | -$548K | -$1.05M | -$46K | -$46K | $0 | $0 | $0 | $0 | $0 | $0 |
| Acquisitions | -$14.86M | -$754K | -$2.34M | -$9.69M | $0 | -$557K | -$9.84M | $27.76M | $0 | $428K | $0 | $0 | $0 | $105K | $0 | $0 | $0 | $0 | $0 | $0 |
| Purchases of Investments | $0 | -$35.3M | $0 | -$9.69M | $0 | -$5M | -$750K | -$11.5M | -$10M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Sales of Investments | $0 | $124.77M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Investing Activities | $0 | $0 | $0 | -$7.35M | -$10M | $0 | $0 | $0 | $0 | -$83.25M | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Investing | -$28.52M | $79.85M | -$39.92M | -$38.17M | -$21.2M | -$16.53M | -$17.45M | $12.55M | -$10.59M | -$503K | -$548K | -$1.05M | -$46K | $59K | $0 | $0 | $0 | $0 | $0 | $0 |
| Financing Activities | ||||||||||||||||||||
| Debt Repaid | $188.31M | $85.66M | $205.56M | -$14.34M | -$220.92M | $3.24M | -$38.87M | $3.1M | -$7.5M | -$6.85M | - | - | - | - | - | - | - | $10K | - | - |
| Common Stock Issuance | $402.33M | $201.82M | $317.87M | $47.7M | $83.61M | $57.93M | $107.99M | $0 | $71.79M | $37.7M | $5.93M | $1.97M | $3.44M | $4.11M | $563K | $690K | $0 | $0 | $0 | $0 |
| Common Stock Repurchases | $0 | $0 | -$55M | $0 | $0 | $0 | -$15.64M | $0 | $0 | $0 | $0 | -$43 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | $1.62M | $15.42M | $98.35M | $8.85M | $211K | -$1.01M | $524K | -$252K | $304K | -$982K | $0 | $13K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Cash from Financing | $311.72M | $181.33M | $174.24M | $78.89M | $326M | $53.67M | $131.74M | -$3.35M | $79.59M | $43.57M | $5.97M | $1.98M | $3.44M | $4.11M | $563K | $690K | $0 | -$10K | $0 | $0 |
| Forex Effect | -$2.37M | $843K | $915K | -$277K | -$135K | $65K | -$36K | $0 | $0 | $0 | $0 | $0 | $0 | $676K | $0 | $0 | $0 | $0 | $0 | $0 |
| Net Change in Cash | -$13.03M | -$19.8M | -$24.3M | -$132.56M | $147.9M | -$61.97M | $43.36M | -$32.86M | $40.23M | $26.58M | $1.62M | -$1.81M | $1.85M | $4.11M | $359K | $22K | $0 | $0 | $0 | $0 |
| Supplementary Data | ||||||||||||||||||||
| Operating Cash Flow | -$293.86M | -$281.82M | -$159.54M | -$173M | -$111.77M | -$99.18M | -$70.89M | -$42.07M | -$28.76M | -$16.49M | -$3.8M | -$2.74M | -$1.55M | -$735K | -$204K | -$668K | $0 | $10K | $0 | $0 |
| Capital Expenditure | -$13.66M | -$8.87M | -$37.58M | -$11.44M | -$21.2M | -$10.97M | -$6.86M | -$3.71M | -$591K | -$931K | -$548K | -$1.05M | -$46K | -$46K | $0 | $0 | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$307.51M | -$290.69M | -$197.12M | -$184.44M | -$132.96M | -$110.15M | -$77.75M | -$45.78M | -$29.36M | -$17.42M | -$4.35M | -$3.8M | -$1.59M | -$780K | -$204K | -$668K | $0 | $10K | $0 | $0 |
| Cash at Beginning | $36.66M | $56.46M | $80.77M | $213.33M | $20.43M | $82.4M | $39.04M | $71.9M | $31.67M | $5.09M | $3.47M | $5.28M | $3.43M | -$676K | $22K | $0 | $0 | $0 | $0 | $0 |
| Cash at End | $23.63M | $36.66M | $56.46M | $80.77M | $168.33M | $20.43M | $82.4M | $39.04M | $71.9M | $31.67M | $5.09M | $3.47M | $5.28M | $3.43M | $380K | $22K | $0 | $0 | $0 | $0 |